MARKET

SABSW

SABSW

SAB BIOTHERAPEUTICS INC
NASDAQ
0.0126
+0.0006
+5.00%
Closed 09:30 06/12 EDT
OPEN
0.0101
PREV CLOSE
0.0120
HIGH
0.0126
LOW
0.0101
VOLUME
9.50K
TURNOVER
--
52 WEEK HIGH
0.1800
52 WEEK LOW
0.0092
MARKET CAP
--
P/E (TTM)
-0.0088
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SABS last week (0601-0605)?
Weekly Report · 4d ago
Weekly Report: what happened at SABS last week (0525-0529)?
Weekly Report · 06/01 09:53
SAB Biotherapeutics to present repeat-dosing clinical data on SAB-142 for new-onset type 1 diabetes at ADA 2026
PUBT · 05/29 12:06
SAB Biotherapeutics to present SAB-142 data at ADA Scientific Sessions
PUBT · 05/29 12:02
Weekly Report: what happened at SABS last week (0518-0522)?
Weekly Report · 05/25 09:55
SAB Biotherapeutics Initiated at Buy by Citigroup
Dow Jones · 05/22 15:15
SAB Biotherapeutics Price Target Announced at $11.00/Share by Citigroup
Dow Jones · 05/22 15:15
Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11
Benzinga · 05/22 15:05
More
About SABSW
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABSW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABSW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABSW stock methods without spending real money on the virtual paper trading platform.